|
ABOUT ACTIVAMUNE
ActivaMuneฎ
is a patented formula exclusively marketed by Berkeley BioSciences, Inc.
under license from the University of California at Berkeley.
The Berkeley BioSciences
Team
Dr. Leonard Bjeldanes, Ph.D., is Professor and
former Chairman of the Nutritional Sciences Department at the University of
California at Berkeley. Dr. Bjeldanes' laboratory is recognized globally for
its innovations in the fields of nutrition and molecular oncology and is
particularly credited for its
pioneering research on Diindolylmethane (DIM).
Dr. Bjeldanes' laboratory was the first to
discover DIM's anti-proliferative effects on prostate cancer cells and
discover its biological mechanism of action, the first to discover DIM's
role in healthy estrogen metabolism, the first to discover DIM's multitude
of anti-proliferative effects on human mammary tumor cells, and more recently, the
first laboratory to discover DIM's unique
immune modulatory properties. This recent discovery helps to shed light on important biomedical questions regarding DIM's efficacy
on RRP tumors and Cervical Dysplasia. It has opened new vistas
for biomedical investigators worldwide and has led to a global effort to
leverage this unique mode of action for a
multitude of diseases: from AIDS, Hepatitis, and Human Papilloma Virus to
most forms of cancer.
Dr. Bjeldanes has authored over 100
publications in prominent scientific journals and is the inventor of
numerous issued and pending patents in the fields of molecular immunology
and oncology, including the patent on the use of DIM for immune modulation
exclusively licensed by Berkeley BioSciences, Inc. Dr. Bjeldanes is a member
of the American Chemical Society, American Association for the Advancement
of Science, American Institute of Nutrition and the Society of Toxicology.
He has served on the Editorial Boards of the Journal of Nutrition, Journal
of Toxicology and Environmental Health, Food Research International and
Chemical Research in Toxicology. Dr. Bjeldanes is a co-founder of Berkeley
BioSciences, Inc. and a member of its Scientific Advisory Board.
Dr. Gary Firestone, Ph.D.,
is Director of the National Institutes of Health Cancer Research Program, Professor of
Molecular and Cell Biology, and former Chairman of the College of Letters
and Science at the University of
California at Berkeley. He is an internationally recognized scientist in the
field of molecular oncology and a highly sought after speaker at
scientific conferences on oncology research. His laboratory is also
recognized for its pioneering work on Diindolylmethane. Dr. Firestone's
laboratory, in collaboration Dr. Bjeldanes', was the first in the world to
conduct a human clinical study on Diindolylmethane supplementation and
demonstrate that it increased the 2-hydroxylation of estrogen
metabolites--an activity regarded by many oncologists to reduce the risk of
breast and prostate cancer. Together, Dr. Firestone and Dr. Bjeldanes as a
team have published more scientific papers on Diindolymethane than any other
scientific team worldwide. Dr. Firestone has published over 100 publications
in prominent scientific journals and is the inventor of multiple issued and
pending patents in the fields of molecular immunology and oncology. He is a
co-inventor on the patent regarding the use of DIM for immune modulation
exclusively licensed by Berkeley BioSciences, Inc. Dr. Firestone has served
on the Editorial Boards of the Journal of Molecular Endocrinology and the
Journal of Experimental Zoology in addition to serving on the grant review
boards of the National Science Foundation and the National Institutes of
Health. He is a member of the American Society of Cell Biology, American
Association of Cancer Research and the American Association for the
Advancement of Science. Dr. Firestone is a co-founder of Berkeley
BioSciences, Inc. and a member of its Scientific Advisory Board.
Dr. Christopher Benz, M.D., is Professor of
Medicine in Oncology at the University of California San Francisco School of
Medicine and Program Director of the Cancer and Developmental Therapeutics
Program at the Buck Institute for Age Research. He is an internationally
recognized scientist in cancer research. When he joined the UCSF Medical
Center in 1983, he established the very first laboratory at UCSF focused on
breast cancer research. He is a practicing oncologist at the UCSF Carol
Franc Buck Breast Care Center, senior member of the UCSF Cancer Center
Breast Oncology Program, faculty member in the UCSF-UC Berkeley Graduate
Program of Bioengineering, and a member of the American Association for
Cancer Research International Aging Taskforce. Dr. Benz is a key participant
in the interdisciplinary team of Buck Institute geroscientists actively
collaborating to better understand and prevent age-associated illnesses like
cancer. A primary goal of Dr. Benz's research has been to understand the
link between aging and cancer: why the incidence of cancer increases with
age, how the biology of cancer is impacted by normal aging, and how to use
this information to improve cancer prevention and treatment. The Benz
laboratory at the Buck Institute focuses on several clinical types of breast
cancer including those that over-express the estrogen receptor (ER), an
age-associated mechanism that drives the most rapidly increasing form of
breast cancer worldwide. Dr. Benz has published over 100 publications in
prominent scientific journals and actively collaborates with the
laboratories of Dr. Bjeldanes and Dr. Firestone at UC Berkeley in the
research of Diindolylmethane as a natural therapeutic for multiple forms of
cancer, including breast cancer. Dr. Benz is a member of the Scientific
Advisory Board of Berkeley BioSciences, Inc.
Dr. Warner Greene, M.D., Ph.D., is Professor
of Medicine in Microbiology and Immunology at the University of California
San Francisco School of Medicine and Director of the Gladstone Institute of
Virology and Immunology at UCSF where he oversees the Institute's vast
biomedical research activities in the fields of immunology and virology.
Regarded as one of the leading figures in the field of immunology, he is a highly sought after speaker in international
biomedical conferences on immunology and immune related diseases. Dr. Greene's
laboratory focuses on the pathogenic interplay of the HIV-1 and HTLV-I human
retroviruses with immune cells. Infection of human hosts with these
retroviruses produces contrasting diseases within the CD4 subset of T
lymphocytes, specifically the Acquired Immune Deficiency Syndrome (AIDS)
with HIV-1 and the Adult T-Cell Leukemia (ATL) with HTLV-1. His laboratory
specializes in exploring the molecular biology of these conditions in
addition to studying the role that Nuclear Factor Kappa Beta (NFkB) plays in inflammatory responses and how a regulation of NFkB activity may affect
different disease conditions. Dr. Greene has published over 100 publications
in prominent scientific journals and is a Fellow of the American Academy for
the Advancement of Science. He is a member of the Executive Board of the
AIDS Research Institute at UCSF and the Institute of Medicine of the United
States National Academy of Sciences. Dr. Greene is a clinical immunologist
at the UCSF Medical Center and is actively collaborating with the
laboratories of Dr. Bjeldanes and Dr. Firestone at UC Berkeley in the
research of Diindolylmethane as a natural therapeutic for multiple forms of
infectious disease and cancer, including AIDS and Leukemia. Dr. Greene is a
member of the Scientific Advisory Board of Berkeley BioSciences, Inc.
Arash Michael Davallou is a summa cum laude
graduate of the Molecular and Cell Biology Department of the University of
California at Berkeley where he was a Howard Hughes and American Heart
Association Biomedical Fellow. He has worked as a Biomedical Investigator in
Molecular Oncology and Immunology at the Lawrence Berkeley National
Laboratory and the Johns Hopkins School of Medicine. Arash holds an MBA from the Harvard Business
School and is the president of The Biotechnology Roundtable--an
international association for business professionals in the life sciences
industry. He
is directly involved in the clinical trials of Diindolylmethane as a natural
therapeutic candidate for a multitude of diseases and oversees the company's
collaboration with biomedical research centers worldwide conducting clinical
investigations on DIM. He is the first person to design and lead a clinical
trial of DIM as an adjuvant to Interferon-gamma, taking into account recent
discoveries on how these molecules interact and synergize with each other at
the cellular level in the expression of the MHC-I complex. Arash is a former member
of the International and Business Committees of the Biotechnology Industry
Organization and former Director of Business Development at BioDiscovery--a DNA microarray discovery services company where he was responsible
for strategic alliances with biotechnology and pharmaceutical companies. He
is a frequently invited speaker and panelist in life science conferences. Arash is co-founder and president of Berkeley
BioSciences, Inc.
Mission
Berkeley BioSciences is dedicated to
helping people lead healthier lives through the
development of first-in-class nutrition and healthcare products based on
rigorous scientific research and proprietary knowledge. The company has two
divisions: nutraceutical and biopharmaceutical. The nutraceutical division
markets ActivaMune and the biopharmaceutical division is researching and
developing nature-based therapeutics for multiple forms of cancer (breast,
prostate, lung, colon, cervical) and infectious diseases (AIDS, SARS, Hepatitis, HPV, Influenza, Pandemic Flu).
DIM is currently one of the compounds actively under investigation as a
natural therapeutic candidate for all of these diseases. The company has
discovery partnerships in place with leading medical centers throughout the
world that are actively investigating DIM and other nature-based compounds
as therapeutics for a number debilitating diseases. ActivaMune sales help
support the research and development efforts of the biopharmaceutical
division and support further biomedical research on naturally occurring
compounds with therapeutic potential.
Contact
To contact ActivaMune, please write to:
ActivaMune
Health Supplement
Customer Service Mailing Center
1434 Westwood Blvd. # 5
Los Angeles, CA 90024
Company Telephone: 1-510-717-7817 (Berkeley,
California)
|
